BiotechTube
Prodo Laboratories

Prodo Laboratories

Irvine, United States· Est.
prodolabs.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

Prodo Laboratories operates as a specialized service provider and research partner in the diabetes field, focusing on the isolation and supply of human and rodent pancreatic islets. Its core value proposition is the use of proprietary, optimized media (PIM series) to improve islet quality for research applications, including drug development and transplantation studies. The company also offers contract research, assay services, and histology expertise, positioning itself as a critical enabler for diabetes research. Founded by renowned islet transplantation pioneer Dr. David Scharp, the company combines deep scientific expertise with a service-oriented business model.

Diabetes

Technology Platform

Proprietary cGMP islet media platform (PIM series) optimized for the recovery, culture, and transport of pancreatic islets, enhancing their viability and functionality for research.

Funding History

2
Total raised:$2.5M
Grant$750K
Seed$1.8M

Opportunities

The growing global diabetes epidemic ensures sustained investment in research, driving demand for high-quality research tools like human islets.
The expansion of cell therapy and regenerative medicine for diabetes creates new needs for benchmarking and characterization services that Prodo Labs could provide.
There is also an opportunity to further commercialize its proprietary media platform to a wider research audience.

Risk Factors

The business is vulnerable to disruptions in the supply of human pancreases from organ procurement networks.
Long-term demand could be threatened if stem-cell derived islets become a superior and widely adopted research model, reducing reliance on primary human islets.
As a niche service provider, the company's growth is inherently tied to the funding cycles and priorities of the diabetes research community.

Competitive Landscape

Prodo Labs operates in a specialized niche with a limited number of other organizations providing human islets for research, such as academic islet isolation centers and a few other service providers. Its primary competition comes from in-house isolations at large research institutions and alternative research models. Its key differentiators are its proprietary media, the scientific prestige of its founder, and its focus on both normal and Type 2 diabetic islets.

More companies in Cell & Gene Therapy →More companies in United States →